Review in Germany for Orion Pharma's levosimendan
2003-07-10 · Orion Corporation, Orion Pharma · original orionpharma.com ↗
The research documentation concerning Orion Corporation Orion Pharma's levosimendan has been taken for review by the German drug authority, in the light of the recent Phase III study results, which Orion Pharma published in June. The statement from the German authority BfArM is expected in the beginning of the last quarter of the year. Orion Corporation Jukka Viinanen Risto Miettunen President and CEO Executive Vice President Contact Person: Risto Miettunen, President, Orion Pharma, phone +358 10 429 4299 Publisher: Orion Corporation Corporate Administration Orionintie 1, FIN-02200 Espoo Homepage: www.orion.fi Heikki Vuonamo, Corporate VP, Communications Phone +358 10 429 4967 [email protected]
The release as fetched from its publisher. orionpharma.com ↗